Benitec Biopharma Inc.

For the period ended Jun 30, 2025. Filed Sep 22, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Sep 22, 2025

BNTC$9.87+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	June 30,2025	June 30,2024
Assets
Current assets:
Cash and cash equivalents	$97,744	$50,866
Restricted cash	113	63
Trade and other receivables	33	229
Prepaid and other assets	628	516
Total current assets	98,518	51,674
Property and equipment, net	131	179
Deposits	55	25
Prepaid and other assets	28	62
Right-of-use assets	860	270
Total assets	$99,592	$52,210
Liabilities and stockholders’ equity
Current liabilities:
Trade and other payables	$1,022	$4,165
Accrued employee benefits	426	475
Lease liabilities, current portion	354	284
Total current liabilities	1,802	4,924
Non-current accrued employee benefits	—	38
Lease liabilities, less current portion	495	—
Total liabilities	2,297	4,962
Stockholders’ equity:
Preferred stock, $0.0001 par value—5,000,000 shares authorized; no shares issued and outstanding at June 30, 2025 and 2024, respectively	—	—
Common stock, $0.0001 par value—160,000,000 shares authorized; 26,250,469 shares and 10,086,119 shares issued and outstanding at June 30, 2025 and 2024, respectively	2	1
Additional paid-in capital	326,308	238,398
Accumulated deficit	(228,176)	(190,259)
Accumulated other comprehensive loss	(839)	(892)
Total stockholders’ equity	97,295	47,248
Total liabilities and stockholders’ equity	$99,592	$52,210

F-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.